You are here: Industry Insights > Sanofi

News List

Dupixent Eosinophilic Esophagitis Trial Meets Both Co-Primary Endpoints americanpharmaceuticalreview
June 01, 2020
Regeneron Pharmaceuticals and Sanofi announced positive results from Part A of the pivotal Phase 3 trial evaluating Dupixent? (dupilumab) in patients 12 years and older with eosinophilic esophagitis (EoE).
Sanofi intends to sell its equity investment in Regeneron; confirms no change to ongoing collaborati worldpharmanews
May 28, 2020
Sanofi announced its intent to sell its equity investment in Regeneron through a registered public offering and related share repurchase by Regeneron.
Sanofi to sell stake in Regeneron pharmatimes
May 27, 2020
Sanofi has revealed its intent to sell its equity investment in Regeneron through a registered public offering and related share repurchase by the firm.
FDA grants priority review to Biologics License Application for sutimlimab europeanpharmaceuticalreview
May 21, 2020
The FDA has granted priority review of the Biologics License Application for sutimlimab to treat haemolysis in patients with cold agglutinin disease (CAD).
Sanofi’s blood cancer drug Sarclisa meets primary endpoint in IKEMA trial pharmaceutical-business-review
May 15, 2020
Sanofi said that its blood cancer drug Sarclisa (isatuximab) has achieved the primary goal of a phase 3 trial in patients with relapsed multiple myeloma.
US likely to get first access to Sanofi’s Covid-19 vaccine candidate pharmaceutical-technology
May 15, 2020
French pharmaceutical giant Sanofi CEO Paul Hudson has said that the US will likely have first access to its Covid-19 vaccine if it succeeds.
Sanofi says its COVID-19 vaccine will available in all countries expresspharma
May 15, 2020
The statement comes after the French government took objection to Sanofi CEO’s comment that the US will get first access to the company’s vaccine.
Sanofi's Sarclisa cuts death risk in mutiple myeloma pharmatimes
May 13, 2020
Sanofi's monoclonal antibody Sarclisa (isatuximab) has hit targets in a late-stage trial, reducing the risk of disease progression or death in patients with relapsed multiple myeloma.
Sanofi/Regeneron's Libtayo shows benefit in BCC pharmatimes
May 08, 2020
Sanofi and Regeneron's Libtayo (cemiplimab) has demonstrated 'clinically meaningful and durable responses' in a subset of patients with basal call carcinoma (BCC) from whom there are currently no approved treatments.
Sanofi’s meningococcal vaccine MenQuadfi secures FDA approval pharmaceutical-technology
April 30, 2020
Sanofi has received the US Food and Drug Administration (FDA) approval for its meningococcal conjugate vaccine, MenQuadfi.